DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

The American Journal of Psychiatry
Todd LenczAnil K Malhotra

Abstract

All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves. Relative to wild type homozygotes, G carriers (A-241G) exhibited a significantly faster time until response, whereas -141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results. These findings suggest that variation in the D(2) receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.

Citations

Sep 29, 2007·Advances in Therapy·Edward KimAndrei Pikalov
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang Maier, Astrid Zobel
Sep 21, 2007·Current Psychiatry Reports·Charles U Nnadi, Anil K Malhotra
Sep 21, 2007·Current Psychiatry Reports·Adriana FosterPeter Buckley
Oct 12, 2010·Psychological Medicine·M CaseB J Kinon
Oct 21, 2009·The Pharmacogenomics Journal·K AitchisonA K Malhotra
Jan 4, 2012·The Pharmacogenomics Journal·B AlmogueraUNKNOWN Spanish Consortium of Pharmacogenetics Research in Schizophrenia
Aug 30, 2008·Schizophrenia Bulletin·Maria J Arranz, Shitij Kapur
Apr 3, 2009·Pharmacogenetics and Genomics·Chadi A CalargeJanet A Schlechte
Jul 29, 2010·Pharmacogenetics and Genomics·Todd LenczAnil K Malhotra
Aug 26, 2010·Pharmacogenetics and Genomics·Huaiyu MiRuss B Altman
Feb 7, 2007·Current Opinion in Psychiatry·Brigitta Bondy, Ilja Spellmann
Dec 24, 2010·Experimental & Molecular Medicine·Kyu Young LeeYong Sik Kim
Sep 24, 2011·The Journal of Clinical Psychiatry·Juan A GallegoJohn M Kane
Dec 18, 2013·Pharmacogenomics·Evangelia Eirini TsermpiniGeorge P Patrinos
Jan 19, 2013·Pharmacogenomics·Adrián LlerenaHumberto Fariñas
Sep 27, 2007·International Review of Psychiatry·Anil K MalhotraJohn M Kane
Nov 26, 2011·Expert Review of Clinical Pharmacology·Maria J Arranz, Janet C Munro
Jan 28, 2010·Expert Opinion on Pharmacotherapy·Falk W Lohoff, Thomas N Ferraro
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Sep 14, 2010·Clinics in Laboratory Medicine·Peter P Zandi, Jennifer T Judy
Sep 14, 2010·Clinics in Laboratory Medicine·Adriana FosterPeter Buckley
Feb 18, 2010·The Psychiatric Clinics of North America·Peter P Zandi, Jennifer T Judy
Dec 9, 2008·Clinics in Laboratory Medicine·Bronwyn Ramey-HartungKristen K Reynolds
Jun 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriSunao Kaneko
Aug 28, 2007·The Psychiatric Clinics of North America·Adriana FosterPeter F Buckley
Dec 21, 2013·British Journal of Clinical Pharmacology·Gavin P ReynoldsCaroline F Dalton
Jul 22, 2014·Human Psychopharmacology·Teresa CabaleiroFrancisco Abad-Santos
Mar 6, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jelle VehofUNKNOWN GROUP investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here